The dose-limiting platelet toxicity associated with BCL-XL inhibitors has led to the development of DT2216, a proteolysis-targeting chimera (PROTAC) that targets the BCL-XL protein for degradation via the Von Hippel-Lindau (VHL) (E3) ligase [106] in a cancer-cell specific manner. Here, BCL2L1 is linked to cancer.